NCT04143425

Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma

Prospective Observational Study of Imaging-based Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastomas

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 15 (actual)
• Sponsor: Ho Sung Kim · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate whether pre-treatment MRI can be used to predict treatment response for anti-angiogenic treatment in glioblastomas.

Detailed description

Although overall the effects on prolonging survival in bevacizumab-treated patients is modest at best, it is still unclear whether there is not a more substantial positive effect in a subset of patients, potentially identifiable by imaging markers. Allowing for prediction of good or bad responder from anti-angiogenic therapy prior to treatment completion is important to select patients most likely to benefit from anti-angiogenic treatment. This is a prospective observational study and no active comparator will be used. Study participants include adult patients with recurrent glioblastoma. We hypothesized that quantifying changes in multi-modal advanced MR imaging techniques would allow early treatment response and long-term prediction in glioblastomas.

Conditions

• Adult Glioblastoma
• Magnetic Resonance Imaging
• Bevacizimab

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	3-Tesla conventional magnetic resonance imaging	T1-weighted, T2-weighted, fluid-attenuated inversion recovery, and contrast-enhanced T1-weighted imaging
DIAGNOSTIC_TEST	Advanced imaging without contrast use	Diffusion-weighted imaging, amide proton transfer-weighted imaging, electrical properties tomography, and 2hG-magnetic resonance spectroscopy
DIAGNOSTIC_TEST	Dynamic susceptibility contrast-weighted imaging	Cerebral blood volume and vessel architectural imaging parameters

Timeline

• Start date: 2020-02-06
• Primary completion: 2021-08-31
• Completion: 2022-11-01
• First posted: 2019-10-29
• Last updated: 2024-05-14

Locations

1 site across 1 country: South Korea